Stockscreener 앱 받기
0.4656
6.88%
-0.0344
시간 외 거래:
.47
0.0044
+0.95%
전일 마감가:
$0.50
열려 있는:
$0.455
하루 거래량:
19,451
Relative Volume:
0.14
시가총액:
$12.97M
수익:
$6.56M
순이익/손실:
$-14.92M
주가수익비율:
-0.8622
EPS:
-0.54
순현금흐름:
$-33.87M
1주 성능:
-15.35%
1개월 성능:
-25.19%
6개월 성능:
-29.45%
1년 성능:
-53.03%
1일 변동 폭
$0.4421
$0.53
1주일 범위
$0.4421
$0.55
52주 변동 폭
$0.334
$1.65
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
SLGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
0.4656 | 12.97M | 6.56M | -14.92M | -33.87M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2019-12-31 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-31 | 재확인 | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd 주식(SLGL)의 최신 뉴스
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal - TipRanks
(PDF) NaFePO4 Particles as a Cathode of Sodium Ion-Battery via Sol-Gel Method: A Review on Synthesis - ResearchGate
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Sol Gel Technologies Ltd expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Uremic Pruritus Clinical and Non-Clinical Studies, Key - openPR
Sol-Gel Technologies (SLGL) to Release Quarterly Earnings on Wednesday - Defense World
Key Driver Transforming The Rosacea Market 2025: Rising Skin Disease Prevalence Fuels Growth In The Rosacea... - WhaTech
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Palmoplantar Keratoderma Clinical and Non-Clinical Studies, - openPR
Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks
Basal Cell Nevus Syndrome Treatment Market Size in the 7MM - openPR
Biotech Stocks Facing FDA Decision In August 2021 - RTTNews
Sol-Gel Technologies Ltd (SLGL) Shares Decline Despite Market Challenges - The News Heater
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Not Doing Enough For Some Investors As Its Shares Slump 51% - Simply Wall St
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Constellium SE’s (CSTM) Stock: A -3.86% Simple Moving Average for the Past 20 Days - The News Heater
Tronox Holdings plc (TROX): A Technical Analysis - The News Heater
PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease - Yahoo Finance
Rosacea Clinical Trials Analysis 2025: EMA, PDMA, FDA - openPR
Appointment of Dr. Bryan Jones as an Advisor to Lead Sol-Gel Special Projects - Yahoo Finance
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Acne Vulgaris Market Size to Reach USD 10.4 Billion by 2035, with a Growth Rate (CAGR) of 3.33% during 2025-2035 - BioSpace
(PDF) Synthesis and Characterization of CZTS Thin Films by Sol-Gel Method without Sulfurization - ResearchGate
Rosacea Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA - openPR
Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management - Dermatology Times
Acne Vulgaris Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Is SolGel Technologies (SLGL) a Great Value Stock Right Now? - Yahoo Finance
There's Reason For Concern Over Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Massive 209% Price Jump - Simply Wall St
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket - Benzinga
United States shares higher at close of trade; Dow Jones Industrial Average up 0.16% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.16% - Investing.com
SLGL Stock Touches 52-Week High at $1.65 Amid Market Fluctuations - Investing.com
The Next-Generation Solar Cell Market Set to Reach $12.91 Billion by 2031. - openPR
Rosacea Treatment Market Growth in Future Scope 2024-2031 | - openPR
Solar Lighting System Market Trends and Future Opportunities 2024-2032 - openPR
Acne Vulgaris Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Global Solar Street Lighting Market to Reach USD 12.38 Billion by 2029, Growing at a CAGR of 14.5% - openPR
Revolutionary Solar Lighting Innovations for 2024 - openPR
Sol-Gel Technologies Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sol-Gel receives Nasdaq compliance extension By Investing.com - Investing.com Nigeria
Sol Gel Technologies Ltd (SLGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):